DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/BF00180817, but it redirected us to https://link.springer.com/article/10.1007/BF00180817. The analysis below is for the second page.

Title[redir]:
A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer | Investigational New Drugs
Description:
The prognosis for advanced non-small cell lung cancer remains poor. Response to chemotherapy is infrequent and overall survival is low. Trans-retinoic acid (tRA), a differentiating agent whose mechanism of action is thought to be different from conventional chemotherapy has activity in preclinical models and low but definite activity in the clinical setting. Its use has been hampered by decrease in bioavailability during continuous administration. We used an interrupted dosing schedule with a drug holiday for tRA that has since been confirmed to restore blood levels in combination with chemotherapy (Cisplatin-VP 16) in 20 patients with stage IIIB and IV non-small cell lung cancer. Ten patients had partial responses among 19 evaluable pts (53%; 95% confidence interval 30–75%) and 4 had minor responses. Neutropenia was the most common acute toxicity-grade 3/4 neutropenia occurring in 90% of patients at some point in the treatment course. Median survival was 25.5 weeks. This regimen of trans-retinoic acid given with drug holiday and chemotherapy has significant activity in advanced non-small cell lung cancer, is fairly well tolerated and is worthy of confirmation in a larger, multi-institutional setting.

Matching Content Categories {📚}

Health & Fitness
Telecommunications
Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't figure out the monetization strategy.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Doi.org might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cancer, google, scholar, cell, lung, acid, nonsmall, chemotherapy, alltransretinoic, advanced, article, phase, treatment, combination, patients, trial, clin, oncol, thiruvengadam, atiba, drug, acute, privacy, cookies, content, tra, activity, therapy, cisretinoic, promyelocytic, data, journal, publish, search, azawi, holiday, access, study, metastatic, treat, squamous, interferon, haematol, leukemia, letter, natl, inst, analysis, information, log,

Topics {✒️}

month download article/chapter multi-institutional setting trans-retinoic acid administered trans-retinoic acid bioavailability related subjects squamous cell carcinoma privacy choices/manage cookies squamous cell cancers cisplatin-vp 16 chemotherapy trans-retinoic acid trans-retinoic acid phase ii toxicity phase ii trial 13-cis-retinoic acid effective combination therapy full article pdf increased pth-rp trans-retinoicoid acid va medical center clinical setting acute promyelocytic leukaemia dose-limiting toxicity lung cancer acute promyelocytic leukemia warrell rp jr miller wh jr plasma drug concentrations european economic area restore blood levels von hoff dd bone marrow transplantation 27 mg/m2/day o'dwyer pj phase ii study multicenter data evaluation interferon alfa-2a conditions privacy policy interrupted dosing schedule interferon alpha-2a pediat hematol/oncol 15 accepting optional cookies transretinoic acid treatment check access instant access cisplatin-vp 16 main content log journal finder publish combination therapy article investigational retinoid “resistance”

Questions {❓}

Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer
         description:The prognosis for advanced non-small cell lung cancer remains poor. Response to chemotherapy is infrequent and overall survival is low. Trans-retinoic acid (tRA), a differentiating agent whose mechanism of action is thought to be different from conventional chemotherapy has activity in preclinical models and low but definite activity in the clinical setting. Its use has been hampered by decrease in bioavailability during continuous administration. We used an interrupted dosing schedule with a drug holiday for tRA that has since been confirmed to restore blood levels in combination with chemotherapy (Cisplatin-VP 16) in 20 patients with stage IIIB and IV non-small cell lung cancer. Ten patients had partial responses among 19 evaluable pts (53%; 95% confidence interval 30–75%) and 4 had minor responses. Neutropenia was the most common acute toxicity-grade 3/4 neutropenia occurring in 90% of patients at some point in the treatment course. Median survival was 25.5 weeks. This regimen of trans-retinoic acid given with drug holiday and chemotherapy has significant activity in advanced non-small cell lung cancer, is fairly well tolerated and is worthy of confirmation in a larger, multi-institutional setting.
         datePublished:
         dateModified:
         pageStart:395
         pageEnd:401
         sameAs:https://doi.org/10.1007/BF00180817
         keywords:
            lung cancer
            retinoic acid
            cisplatin
            etoposide
            clinical trial
            Oncology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Investigational New Drugs
            issn:
               1573-0646
               0167-6997
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Raghu Thiruvengadam
               affiliation:
                     name:VA Medical Center and University of California
                     address:
                        name:Department of Medicine, VA Medical Center and University of California, Irvine
                        type:PostalAddress
                     type:Organization
                     name:VA Medical Center
                     address:
                        name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joshua O. Atiba
               affiliation:
                     name:VA Medical Center and University of California
                     address:
                        name:Department of Medicine, VA Medical Center and University of California, Irvine
                        type:PostalAddress
                     type:Organization
                     name:VA Medical Center
                     address:
                        name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Samar H. Azawi
               affiliation:
                     name:VA Medical Center and University of California
                     address:
                        name:Department of Medicine, VA Medical Center and University of California, Irvine
                        type:PostalAddress
                     type:Organization
                     name:VA Medical Center
                     address:
                        name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer
      description:The prognosis for advanced non-small cell lung cancer remains poor. Response to chemotherapy is infrequent and overall survival is low. Trans-retinoic acid (tRA), a differentiating agent whose mechanism of action is thought to be different from conventional chemotherapy has activity in preclinical models and low but definite activity in the clinical setting. Its use has been hampered by decrease in bioavailability during continuous administration. We used an interrupted dosing schedule with a drug holiday for tRA that has since been confirmed to restore blood levels in combination with chemotherapy (Cisplatin-VP 16) in 20 patients with stage IIIB and IV non-small cell lung cancer. Ten patients had partial responses among 19 evaluable pts (53%; 95% confidence interval 30–75%) and 4 had minor responses. Neutropenia was the most common acute toxicity-grade 3/4 neutropenia occurring in 90% of patients at some point in the treatment course. Median survival was 25.5 weeks. This regimen of trans-retinoic acid given with drug holiday and chemotherapy has significant activity in advanced non-small cell lung cancer, is fairly well tolerated and is worthy of confirmation in a larger, multi-institutional setting.
      datePublished:
      dateModified:
      pageStart:395
      pageEnd:401
      sameAs:https://doi.org/10.1007/BF00180817
      keywords:
         lung cancer
         retinoic acid
         cisplatin
         etoposide
         clinical trial
         Oncology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Investigational New Drugs
         issn:
            1573-0646
            0167-6997
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Raghu Thiruvengadam
            affiliation:
                  name:VA Medical Center and University of California
                  address:
                     name:Department of Medicine, VA Medical Center and University of California, Irvine
                     type:PostalAddress
                  type:Organization
                  name:VA Medical Center
                  address:
                     name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joshua O. Atiba
            affiliation:
                  name:VA Medical Center and University of California
                  address:
                     name:Department of Medicine, VA Medical Center and University of California, Irvine
                     type:PostalAddress
                  type:Organization
                  name:VA Medical Center
                  address:
                     name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Samar H. Azawi
            affiliation:
                  name:VA Medical Center and University of California
                  address:
                     name:Department of Medicine, VA Medical Center and University of California, Irvine
                     type:PostalAddress
                  type:Organization
                  name:VA Medical Center
                  address:
                     name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Investigational New Drugs
      issn:
         1573-0646
         0167-6997
      volumeNumber:14
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:VA Medical Center and University of California
      address:
         name:Department of Medicine, VA Medical Center and University of California, Irvine
         type:PostalAddress
      name:VA Medical Center
      address:
         name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
         type:PostalAddress
      name:VA Medical Center and University of California
      address:
         name:Department of Medicine, VA Medical Center and University of California, Irvine
         type:PostalAddress
      name:VA Medical Center
      address:
         name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
         type:PostalAddress
      name:VA Medical Center and University of California
      address:
         name:Department of Medicine, VA Medical Center and University of California, Irvine
         type:PostalAddress
      name:VA Medical Center
      address:
         name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Raghu Thiruvengadam
      affiliation:
            name:VA Medical Center and University of California
            address:
               name:Department of Medicine, VA Medical Center and University of California, Irvine
               type:PostalAddress
            type:Organization
            name:VA Medical Center
            address:
               name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
               type:PostalAddress
            type:Organization
      name:Joshua O. Atiba
      affiliation:
            name:VA Medical Center and University of California
            address:
               name:Department of Medicine, VA Medical Center and University of California, Irvine
               type:PostalAddress
            type:Organization
            name:VA Medical Center
            address:
               name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
               type:PostalAddress
            type:Organization
      name:Samar H. Azawi
      affiliation:
            name:VA Medical Center and University of California
            address:
               name:Department of Medicine, VA Medical Center and University of California, Irvine
               type:PostalAddress
            type:Organization
            name:VA Medical Center
            address:
               name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Medicine, VA Medical Center and University of California, Irvine
      name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
      name:Department of Medicine, VA Medical Center and University of California, Irvine
      name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
      name:Department of Medicine, VA Medical Center and University of California, Irvine
      name:Department of Radiation Oncology, VA Medical Center, Long Beach, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(103)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.98s.